Expertise in
42
conditions

Dr. Sheetal Acharya

Hematology
Up Health System-Marquette | Cancer Center
850 W Baraga Ave, 
Marquette, MI 
Offers Telehealth
Expertise in
42
conditions
Up Health System-Marquette | Cancer Center
850 W Baraga Ave, 
Marquette, MI 

Overview

Sheetal Acharya is a Hematologist in Marquette, Michigan. Dr. Acharya is highly rated in 42 conditions, according to our data. Her top areas of expertise are Adrenocortical Carcinoma, Testicular Cancer, Teratoma of the Mediastinum, Adrenal Cancer, and Orchiectomy.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Specialist in MI

Hospital Affiliations

Bell Hospital
Baraga County Memorial Hospital
Uphs Marquette Dlp Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Up Health System-Marquette | Cancer Center
850 W Baraga Ave, Marquette, MI 49855

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 9 Less Clinical Trials

5 Total Publications

Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.
Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.
Journal: Current drug delivery
Published: July 22, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology

Marquette General Hospital

1414 W Fair Ave Ste 332, 
Marquette, MI 
 (0.1 miles away)
906-225-3922
Languages Spoken:
English
See accepted insurances

Ross Siemers is a Hematologist and an Oncologist in Marquette, Michigan. Dr. Siemers is highly rated in 19 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML).

Anthony J. Jaslowski
Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine
Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (56.4 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Anthony Jaslowski is a Hematologist and an Internal Medicine provider in Escanaba, Michigan. Dr. Jaslowski is highly rated in 51 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, Bone Marrow Aspiration, and Myringotomy.

Brian L. Burnette
Expertise in
42
conditions
Dr. Brian L. Burnette
Hematology | Oncology
Expertise in
42
conditions
Dr. Brian L. Burnette
Hematology | Oncology

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (56.4 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Brian Burnette is a Hematologist and an Oncologist in Escanaba, Michigan. Dr. Burnette is highly rated in 42 conditions, according to our data. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Sheetal Acharya

How do I make an appointment with Dr. Sheetal Acharya?

You can book an appointment with Dr. Sheetal Acharya by calling their office at 906-449-3900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sheetal Acharya a top-rated expert for Adrenocortical Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sheetal Acharya is classified as an Distinguished expert for Adrenocortical Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sheetal Acharya specialize in?

While Dr. Sheetal Acharya is a Hematology, they have specific expertise in Adrenocortical Carcinoma, Testicular Cancer, and Teratoma of the Mediastinum. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sheetal Acharya participate in research or clinical trials?

Yes. Dr. Sheetal Acharya has published 5 articles and abstracts on conditions like Adrenocortical Carcinoma. You can view a list of Dr. Sheetal Acharya's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sheetal Acharya accept my insurance?

Dr. Sheetal Acharya accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 906-449-3900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acharya's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 32 Advanced Conditions
    View All 144 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile